福建广生堂药业股份有限公司关于公司申请向特定对象发行股票的审核问询函回复（修订稿）及募集说明书等申请文件更新的提示性公告

Group 1 - The company received an inquiry letter from Shenzhen Stock Exchange regarding its application for a private placement of shares on June 13, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough study and response to the inquiry letter, updating the prospectus and application documents accordingly [1][2] - The issuance of shares to specific targets requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, with uncertainties regarding the approval timeline [2] Group 2 - The company disclosed updates and revisions to the inquiry response and application documents on August 29, 2025 [2] - The company commits to timely information disclosure based on the progress of the share issuance matter [2]